Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peptide YY (3-36) is a naturally occurring 34-amino acid peptide (a truncated form of the 36-amino acid PYY) that acts as a selective agonist for the Neuropeptide Y receptor type 2 (NPY2R). It is secreted by the L-cells of the gastrointestinal tract in response to food intake and is a key mediator of postprandial satiety. University College London (UCL) is investigating an oral solution formulation of PYY (3-36) to explore the mechanistic role of lingual PYY receptors in regulating appetite, energy intake, and food preference. By targeting receptors on the tongue and in the oral cavity, this approach aims to understand how early sensory signaling of PYY contributes to weight management and the treatment of obesity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peptide YY (3-36).